Forward Stock Analysis

FWP -  USA Stock  

USD 7.08  0.21  2.88%

The recent indifference towards the small price fluctuations of Forward Pharma Ads could raise concerns from insiders as the firm it trading at a share price of 7.08 on 34,600 in volume. The company executives did not add any value to Forward Pharma investors in May. However, most investors can still diversify their portfolios with Forward Pharma Ads to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.41. The current volatility is consistent with the ongoing market swings in May 2021 as well as with Forward Pharma unsystematic, company-specific events.
Please check Investing Opportunities.

Search Stock Analysis 

 
Refresh
The Forward Pharma stock analysis report makes it easy to digest most publicly released information about Forward Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Forward stock analysis module also helps to analyze the Forward Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Forward Stock Analysis Notes

About 14.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.64. Some equities with similar Price to Book (P/B) outperform the market in the long run. Forward Pharma Ads has Price/Earnings To Growth (PEG) ratio of 0.08. The entity recorded a loss per share of 0.98. The firm next dividend is scheduled to be issued on the 12th of September 2017. Forward Pharma had 1-7 split on the 6th of December 2019. Previously, it operated as a biopharmaceutical company that focused on developing proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. The company was incorporated in 2005 and is headquartered in Copenhagen, Denmark. Forward Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To learn more about Forward Pharma Ads call Claus Svendsen at 45 33 44 42 42 or check out http://www.forward-pharma.com.

Forward Pharma Ads Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Forward Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Forward Pharma Ads or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company reported the last year's revenue of 1.12 B. Reported Net Loss for the year was (6.45 M) with loss before taxes, overhead, and interest of (25 M).
Forward Pharma Ads has about 79.09 M in cash with (5.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Forward Pharma Ads has a frail financial position based on the latest SEC disclosures
Latest headline from www.biospace.com: Midatech Pharma PLC Announces Breakthrough Data Using Q-Sphera Technology - BioSpace

Forward Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Forward Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Forward Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Forward Pharma Ads specific information freely available to individual and institutional investors to make a timely investment decision.
8th of June 2021
Other Events
View
28th of May 2021
Other Events
View
27th of May 2021
Other Events
View
4th of May 2021
Other Events
View
15th of April 2021
Other Events
View
16th of February 2021
Unclassified Corporate Event
View
11th of February 2021
Unclassified Corporate Event
View
12th of January 2021
Other Events
View

Forward Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Forward Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Forward Pharma Ads backward and forwards among themselves. Forward Pharma's institutional investor refers to the entity that pools money to purchase Forward Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Bvf IncCommon Shares647.3 K4.4 M
Morgan StanleyCommon Shares179.7 K1.2 M
Renaissance Technologies LlcCommon Shares63.7 K436 K
Acadian Asset Management LlcCommon Shares46.3 K317 K
Resources Investment Advisors LlcCommon Shares14.1 K96 K
Citadel Advisors LlcCommon Shares13.5 K93 K
Ubs Group AgCommon Shares599K
Note, although Forward Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Forward Market Capitalization

The company currently falls under 'Micro-Cap' category with total capitalization of 51.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Forward Pharma's market, we take the total number of its shares issued and multiply it by Forward Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Forward Profitablity

Forward Pharma's profitability indicators refer to fundamental financial ratios that showcase Forward Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Forward Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Forward Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Forward Pharma's profitability requires more research than a typical breakdown of Forward Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.08) (0.09) 
Return on Average Equity(0.08) (0.09) 
Return on Invested Capital 27.33  29.48 
Return on Sales 0.85  0.85 

Management Efficiency

The entity has Return on Asset of (2.68) % which means that on every $100 spent on asset, it lost $2.68. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (8.26) %, meaning that it generated no profit with money invested by stockholders. Forward Pharma management efficiency ratios could be used to measure how well forward pharma ads manages its routine affairs as well as how well it operates its assets and liabilities. As of 19th of June 2021, Return on Invested Capital is likely to grow to 29.48, while Return on Average Assets are likely to drop (0.09) . As of 19th of June 2021, Total Liabilities is likely to grow to about 1.1 M. Also, Current Liabilities is likely to grow to about 1.1 M
Last ReportedProjected for 2021
Book Value per Share 11.58  17.82 
Enterprise Value over EBIT 5.00  5.39 
Enterprise Value over EBITDA 4.63  4.99 
Price to Book Value 0.61  0.89 
Tangible Assets Book Value per Share 11.74  12.05 
Enterprise Value-29.9 M-30.6 M
Tangible Asset Value79.7 M101.7 M

Technical Drivers

As of the 19th of June, Forward Pharma shows the Coefficient Of Variation of 2789.02, downside deviation of 2.37, and Mean Deviation of 1.77. Forward Pharma Ads technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and break down nineteen technical drivers for Forward Pharma Ads, which can be compared to its rivals. Please confirm Forward Pharma Ads variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Forward Pharma Ads is priced favorably, providing market reflects its regular price of 7.08 per share. Given that Forward Pharma has jensen alpha of 0.0686, we urge you to verify Forward Pharma Ads's prevailing market performance to make sure the company can sustain itself at a future point.

Forward Pharma Ads Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Forward Pharma Ads more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Forward Pharma Predictive Daily Indicators

Forward Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Forward Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Forward Pharma Forecast Models

Forward Pharma time-series forecasting models is one of many Forward Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Forward Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Forward Pharma Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Forward Pharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Forward shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Forward Pharma. By using and applying Forward Stock analysis, traders can create a robust methodology for identifying Forward entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin 0.85  0.85 
Gross Margin 0.88  0.87 
Profit Margin 0.66  0.65 
Previously, it operated as a biopharmaceutical company that focused on developing proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. The company was incorporated in 2005 and is headquartered in Copenhagen, Denmark. Forward Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.

Current Forward Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Forward analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Forward analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
39.0Strong Buy2Odds
Forward Pharma Ads current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Forward analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Forward stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Forward Pharma Ads, talking to its executives and customers, or listening to Forward conference calls.
Forward Analyst Advice Details

Forward Stock Analysis Indicators

Forward Pharma Ads stock analysis indicators help investors evaluate how Forward Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Forward Pharma shares will generate the highest return on investment. By understating and applying Forward Pharma stock analysis, traders can identify Forward Pharma position entry and exit signals to maximize returns.
Shares Percent Shares Out0.02%
Quick Ratio74.18
Fifty Two Week Low5.80
Forward Price Earnings-4.70
Float Shares1.39M
Fifty Two Week High10.15
Shares Short Prior Month7.31k
Average Daily Volume Last 10 Day986.18k
Average Daily Volume In Three Month114.58k
Enterprise Value To Ebitda7.34
Fifty Day Average7.55
Two Hundred Day Average7.30
Please check Investing Opportunities. Note that the Forward Pharma Ads information on this page should be used as a complementary analysis to other Forward Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Forward Pharma Stock analysis

When running Forward Pharma Ads price analysis, check to measure Forward Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forward Pharma is operating at the current time. Most of Forward Pharma's value examination focuses on studying past and present price action to predict the probability of Forward Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Forward Pharma's price. Additionally, you may evaluate how the addition of Forward Pharma to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
The market value of Forward Pharma Ads is measured differently than its book value, which is the value of Forward that is recorded on the company's balance sheet. Investors also form their own opinion of Forward Pharma's value that differs from its market value or its book value, called intrinsic value, which is Forward Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Forward Pharma's market value can be influenced by many factors that don't directly affect Forward Pharma Ads underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Forward Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Forward Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Forward Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.